Technical Analysis for OPTN - OptiNose, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical OPTN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | -2.08% | |
| Reversal New Lows Setup | Bearish Swing Setup | -2.08% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2019
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation
Medicine Pharmaceutical Clinical Medicine Organ Systems Disease Inflammation Respiratory Therapy Allergy Glucocorticoids Sinusitis
Medicine Pharmaceutical Clinical Medicine Organ Systems Disease Inflammation Respiratory Therapy Allergy Glucocorticoids Sinusitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more OPTN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 30.0 |
| 52 Week Low | 5.66 |
| Average Volume | 148,807 |
| 200-Day Moving Average | 10.0146 |
| 50-Day Moving Average | 9.7358 |
| 20-Day Moving Average | 9.5465 |
| 10-Day Moving Average | 8.978 |
| Average True Range | 0.6501 |
| ADX | 19.85 |
| +DI | 11.9192 |
| -DI | 26.7081 |
| Chandelier Exit (Long, 3 ATRs ) | 9.0897 |
| Chandelier Exit (Short, 3 ATRs ) | 9.8303 |
| Upper Bollinger Band | 11.1004 |
| Lower Bollinger Band | 7.9926 |
| Percent B (%b) | 0.0 |
| BandWidth | 32.554339 |
| MACD Line | -0.3848 |
| MACD Signal Line | -0.1743 |
| MACD Histogram | -0.2105 |
| Fundamentals | Value |
|---|---|
| Market Cap | 302.09 Million |
| Num Shares | 37.8 Million |
| EPS | -19.61 |
| Price-to-Earnings (P/E) Ratio | -0.41 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.01 | ||||
| Resistance 3 (R3) | 9.08 | 8.81 | 8.84 | ||
| Resistance 2 (R2) | 8.81 | 8.56 | 8.78 | 8.78 | |
| Resistance 1 (R1) | 8.41 | 8.40 | 8.28 | 8.34 | 8.73 |
| Pivot Point | 8.14 | 8.14 | 8.08 | 8.11 | 8.14 |
| Support 1 (S1) | 7.74 | 7.89 | 7.61 | 7.67 | 7.27 |
| Support 2 (S2) | 7.47 | 7.73 | 7.44 | 7.22 | |
| Support 3 (S3) | 7.07 | 7.47 | 7.16 | ||
| Support 4 (S4) | 7.00 |
